Evolocumab Is Effective and Safe for People With and Without Diabetes

Date: 
September, 2017

September 15, 2017. Evolocumab is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor that reduced cardiovascular (CV) events and low-density lipoprotein cholesterol over a median of 2.2 years in the randomized FOURIER trial (N=27,564). This prespecified post-hoc analysis investigated the efficacy and safety of evolocumab vs placebo among patients with (n=11,031) and without diabetes (n=16,533) at baseline. The impact of evolocumab on the risk of developing diabetes also was investigated. Researchers found that evolocumab reduced the risk of CV outcomes (a composite of CV death, myocardial infarction [MI], stroke, hospital admission for unstable angina, or coronary revascularization) by 17% (P<0.0008) and 13% (P<0.0052) among patients with and without diabetes, respectively. Furthermore, evolocumab reduced the risk of a secondary CV endpoint (a composite of CV, MI, or stroke) by 18% and 22% among patients with and without diabetes, respectively. Finally, researchers found that evolocumab did not increase the risk of developing diabetes among patients without diabetes at baseline. The adverse event profile among all treatment arms was similar. To learn more, read the abstract here